Department of Surgery, McGill University, and Hepatopancreatobiliary and Transplant Surgery Program, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC.
Curr Oncol. 2010 Oct;17(5):67-9. doi: 10.3747/co.v17i5.609.
Advanced hepatocellular carcinoma has a dismal prognosis, with a median overall survival of 7.9 months if untreated and of 10.7 months if treated with sorafenib. We present a case of advanced previously unresectable hepatocellular carcinoma in a 49-year-old man that achieved a pathologic complete response and was made amenable to surgery with sorafenib in combination with (90)Y radioembolization. The patient's survival was more than double the median for patients treated with sorafenib alone.
晚期肝细胞癌预后较差，如果未经治疗，中位总生存期为 7.9 个月，如果用索拉非尼治疗则为 10.7 个月。我们报告了一例 49 岁男性的晚期不可切除肝细胞癌病例，该患者在接受索拉非尼联合（90）钇放射性栓塞治疗后获得了病理完全缓解，并可进行手术。该患者的生存时间是单独接受索拉非尼治疗患者的中位数的两倍多。
